Results for tag: "HUMIRA Biosimilars"

In the field of biotechnology, HUMIRA (adalimumab) biosimilars represent one of the most notable developments in recent years. HUMIRA is a monoclonal antibody originally developed by AbbVie Inc. to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease, among others. As the patents for HUMIRA began to expire, opportunities arose for the development of biosimilars. Biosimilars are highly similar versions of biologic medical products whose patents have expired, developed to be clinically equivalent in terms of safety and efficacy to the original product. The entry of HUMIRA biosimilars into the market has been welcomed by healthcare systems and patients due to the potential for reduced costs and increased access to treatment. Several companies have ventured into the HUMIRA biosimilar market, driven by the extensive use of the reference biologic in therapeutic areas and the anticipated lower price points of biosimilars. Among them are Amgen with its product Amjevita, Samsung Bioepis entering with Hadlima, and Boehringer Ingelheim with Cyltezo. Sandoz, the generic division of Novartis, has also brought Hyrimoz to the market. These companies, alongside others vying for market share, are contributing to the expanding ecosystem of biosimilar alternatives that offer comparable therapeutic benefits to the original biologics. Show Less Read more